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Background. Virus infections result in a range of clinical outcomes for the host, from asymptomatic to severe or even lethal dis-
ease. Despite global efforts to prevent and treat virus infections to limit morbidity and mortality, the continued emergence and re-e-
mergence of new outbreaks as well as common infections such as influenza persist as a health threat. Challenges to the prevention of 
severe disease after virus infection include both a paucity of protective vaccines as well as the early identification of individuals with 
the highest risk that may require supportive treatment.
Methods. We completed a screen of mice from the Collaborative Cross (CC) that we infected with influenza, severe acute respi-
ratory syndrome-coronavirus, and West Nile virus.
Results. The CC mice exhibited a range of disease manifestations upon infections, and we used this natural variation 
to identify strains with mortality after infection and strains exhibiting no mortality. We then used comprehensive preinfection 
immunophenotyping to identify global baseline immune correlates of protection from mortality to virus infection.
Conclusions. These data suggest that immune phenotypes might be leveraged to identify humans at highest risk of adverse 
clinical outcomes upon infection, who may most benefit from intensive clinical interventions, in addition to providing insight for 
rational vaccine design.
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Virus infections lead to significant morbidity and mortality 
worldwide. Although prophylactic vaccinations exist for some 
infections, we lack vaccines against many pathogens, and the 
continued emergence of new viral outbreaks drives a constant 
arms race to limit human disease associated with viruses. One 
barrier to the design of disease prevention strategies is a lack 
of knowledge of natural immune correlates of protection from 
infection and from disease and death. Without this information 
about the types of immune responses that need to be gener-
ated, the design of vaccines or other immune-modulating ther-
apies will remain an empirical, unpredictable process. However, 
immune correlates are difficult to identify and require either a 
case-control clinical study with prospectively collected samples 
or a large, prolonged longitudinal study of immune responses 
in infected individuals pre- and postinfection. In addition, find-
ings regarding immunity to one type of infection may not prove 
useful in application against another infection, and so under-
standing what types of immune responses might be universal in 
combatting many or all viruses would pave the way for a wide-
spread effort to combat multiple viruses simultaneously.
Study of immunity in small animal models such as mice has 
provided a wealth of data on immunity to infection. Advantages 
of these animal models include (1) the ability to easily study im-
munity at pre- and postinfection timepoints as well as (2) a high 
degree of control over both genetics, infection route, and envi-
ronmental factors that result in extremely reproducible datasets. 
However, the latter is also a disadvantage when a single strain of 
mice is used for infection studies, because inbred mice lack ge-
netic diversity. Therefore, these inbred strains typically respond 
reproducibly to infection, thereby preventing the elucidation of 
immune correlates of protection for a genetically diverse popu-
lation such as humans. To overcome these barriers, we used the 
Collaborative Cross (CC). The CC is a population of recombi-
nant inbred mouse strains with high levels of standing genetic 
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variation. The CC strains are derived from 8 founder mouse 
strains that include 5 classic inbred strains and 3 wild-derived 
strains [1–4]. We and others have previously shown that the CC 
can be used to model the diversity in human immune responses 
and reproduce human disease states not captured in standard 
inbred mouse models [5–14], and we additionally demon-
strated that the CC better represents the large diversity in T-cell 
immunophenotypes represented in the human population [15]. 
Thus, the CC affords us with the ability to study immunity and 
clinical disease to infection in an animal model with diverse 
genotypes. In this study, we used a large screen of mice from CC 
F1 crosses (CC-RIX, CC recombinant intercross) infected with 
3 distinct viruses—H1N1 influenza (flu), severe acute respira-
tory syndrome-coronavirus (SARS-CoV), and West Nile virus 
(WNV)—to reveal novel baseline immune correlates associated 
with protection from mortality after infection.
METHODS
Mice
The CC-RI mice were obtained from the Systems Genetics Core 
Facility at the University of North Carolina-Chapel Hill (UNC) 
[16]. Between 2012 and 2017, CC-F1 mice (CC-RIX) were gen-
erated for this research study at UNC in a specific pathogen-free 
(SPF) facility based on the following principles: (1) each CC-RI 
strain used in an F1 cross had to have been certified distribut-
able [16]; (2) the UNC Systems Genetics Core Facility was able 
to provide us sufficient breeding animals for our program to 
generate N = 100 CC-F1 animals in a target 3-month window; 
(3) each CC-RIX had to have 1 parent with an H2Bb haplotype
(from either the C57BL/6J or 129S1/SvImJ founders), and 1
parent with a haplotype from the other 6 CC founder strains; (4) 
each CC-RI had to be used at least 1× (preferably 2×) as a Dam,
and 1× (preferably 2×) as a Sire in the relevant CC-RIX; (5) fi-
nally, we included 2 CC-RIX multiple times across the 5 years
of this program to specifically assess and control for batch and
seasonal effects. The use of CC-RIX allowed us to explore more
lines than the more limited number of available RI strains, and,
in addition, CC-RIX lines were bred to ensure that lines were
heterozygous at the H-2b locus, having 1 copy of the H-2b
haplotype and 1 copy of the other various haplotypes. This de-
sign was selected such that we could examine antigen-specific
T-cell responses for our parallel studies of immunogenetics of
virus infection, while concurrently maintaining genetic varia-
tion throughout the rest of the genome.
Six- to eight-week-old F1 hybrid male mice were transferred 
from UNC to the University of Washington (UW) and housed 
directly into a biosafety level (BSL)-2+ laboratory within an SPF 
barrier facility. Male 8- to 10-week-old mice were used for all 
baseline immune and WNV experiments, with 3–6 mice per 
experimental group. Concurrently, 6- to 8-week-old female F1 
hybrid mice were transferred to either a BSL-3 (SARS-CoV) or 
a BSL-2 cubicle facility (influenza) at UNC, where mice were 
allowed to acclimate for 2 weeks before infection (at 8–10 weeks 
of age). All animal experiments were approved by the UW or 
UNC Institutional Animal Care and Use Committee. The Office 
of Laboratory Animal Welfare of National Institutes of Health 
approved the UNC (no. A3410-01) and the UW (no. A3464-
01), and this study was carried out in strict compliance with 
the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals.
Virus and Infection
West Nile virus TX-2002-HC (WN-TX) was propagated as pre-
viously described [17]. Mice were subcutaneously (s.c.) inocu-
lated in the rear footpad with 100 plaque-forming units (PFU) 
WN-TX. Mice were monitored daily for morbidity (percentage 
of initial weight loss) and clinical disease scores [18]. Mouse-
adapted SARS-CoV MA15 was propagated and tittered on Vero 
cells as previously described [11, 19]. Mice were intranasally in-
fected with 105 PFU of SARS-CoV MA15 and measured daily 
for weight loss. Mice exhibiting extreme weight loss or signs 
of clinical disease were observed 3 times a day and euthanized 
if necessary based on humane endpoints. Influenza virus A/
Ca/04/09 (H1N1) was generated from a reverse genetics system 
in MDCK cells [20]. Mice were inoculated intranasally with 
5000 PFU of this virus in 50 μL phosphate-buffered saline. Mice 
were monitored daily for morbidity and mortality.
Each virus inoculum dose was selected based on doses that 
caused a range of susceptibility phenotypes in the 8 founder 
strains. Previous studies for all viruses were done on a C57BL/6 
background, so this dose was then tested in the founder lines 
to ensure a range of susceptibility, mortality, and immune re-
sponses. For example, 30% of C57BL/6 mice succumb to 100 
PFU WNV delivered s.c., with some other founder lines having 
greater than 50% mortality and others no mortality. We aimed 
to maximize phenotypic diversity while still maintaining suffi-
cient survival such that we could assess immune phenotypes at 
various times postinfection.
Flow Cytometry
Spleens were prepared for flow cytometry staining as previously 
described [5, 6, 15, 18]. All antibodies were tested using cells 
from the 8 CC founder strains to confirm that antibody clones 
were compatible with the CC before being used for testing.
Statistical Analysis
When comparing groups, Mann-Whitney tests were conducted, 
with P < .05 considered significant. Error bars are ±standard 
error of the mean.
RESULTS
Altered Baseline T-Cell Ratio and Phenotypes Associated With Protection 
From Mortality After Virus Infections
Although many studies have sought to identify immune correl-
ates of protection from single virus infections, we used multiple 
infection models to identify globally conserved immune correl-
ates of protection from mortality after virus infection. Thus, we 
used infection of mice with 3 different viruses: flu and SARS-
CoV, which infect the respiratory tract of the host, as well as 
WNV, which is a mosquito-borne neurotropic infection. We fo-
cused on mortality as an endpoint to indicate severe disease, be-
cause the unique clinical manifestations of each infection makes 
scoring difficult. In this screen, 18–28 mice each from over 100 
different CC-RIX lines were infected with each of the 3 viruses, 
followed by monitoring for survival up to 28 days postinfection. 
For this analysis, we identified CC-RIX that had no mortality 
after infection with any of the 3 viruses (“No mortality”) and 
lines that had some degree of mortality to all 3 (“Mortality in all 
three”). This resulted in identification of 8 lines with no mor-
tality and 11 lines with mortality to all 3, providing a high and 
low susceptibility cohort for downstream studies (Table 1). The 
other ~80 CC-RIX had intermediate mortality phenotypes, or 
lacked immune cell phenotypic data, and were not included in 
the subsequent analysis but are listed in Supplementary Table 1.
To determine baseline immune signatures that correlate 
with mortality, we then examined the frequency of different 
populations and phenotypes of T cells within the spleen at 
steady state by assessment of a second cohort of age-matched 
mice from each of these lines (Supplementary Figure S1). We 
found a statistically lower CD4:CD8 T-cell ratio preinfection 
in mice from lines that experienced no mortality after any of 
the infections (Figure 1A). There was no difference in the fre-
quency of CD3+ T cells or the frequency of CD3+ T cells that 
were CD4+, but there was a significantly lower higher frac-
tion of CD3+ T cells that were CD8+ in mice from lines that 
experienced no mortality after infection with WNV, SARS-
CoV, or flu (Figure 1A). These data suggested that higher 
baseline CD8 T-cell levels compared to CD4 T cells correlated 
with reduced risk of mortality. Along with this difference in 
CD4 and CD8 T-cell ratio, there were significantly elevated 
frequencies of memory-phenotype-like, CD44+ CD8 and 
CD4 T cells in mice from lines with no mortality after infec-
tion with any of the 3 viruses (Figure 1B and C). In addition 
to an increased frequency of CD44+ T cells correlating with 
survival upon infection, there are also increased preinfection 
frequencies of activated CD4 and CD8 T cells present in mice 
from lines that survive a subsequent infection. In partic-
ular, there are increased frequencies of CXCR3+CD8 T cells 
(Figure 1D), CD62L−CD4 T cells (Figure 1E), and Ki67+CD4 
T cells (Figure 1F). Thus, the presence of an increased frac-
tion of activated T cells that have recently proliferated and/
or are poised to respond to signals that direct them out of 
lymphoid tissue and into distant tissue sites where virus is 
actively replicating may also confer a survival advantage after 
virus infections. These data, taken together, suggest that mice 
resistant to infection-induced mortality maintain a skew to-
wards higher CD8 T-cell levels with higher baseline T-cell ac-
tivity than animals with lower survival.
Building from these findings, we next assessed the frequency 
of baseline splenic T cells that expressed the transcription factor 
Tbet, which indicates a Th1 phenotype linked with secretion 
of interferon (IFN)γ, known to be a potent antiviral cyto-
kine [21]. Although there is no difference in Tbet expression 
by CD8 T cells between no mortality versus mortality groups 
(Figure 1G), there is a statistically significant increase in Tbet+ 
CD4 T cells in lines with no mortality (Figure 1H). We hypoth-
esize that this may predispose CD4 T cells in mice from these 
lines to rapidly participate in the antiviral response. In contrast, 
there is an increase in the frequency of inducible costimulator 
(ICOS)+CD4+ T cells in lines with mortality (Figure 1I). It has 
been demonstrated that ICOS plays a role in immunity to virus 
infections including flu, lymphocytic choriomeningitis  virus, 
and vesicular stomatitis virus, at the level of antibody re-
sponses, germinal center formation, and CD4 T-cell responses 
[22], thereby suggesting that a steady-state reduction in ICOS 
expression by CD4+ T cells could result in impaired antiviral 
responses. However, it is also possible that attenuated immunity 
after infection could result in diminished immune-mediated 
pathology and could benefit the host in terms of survival. 
Indeed, although a robust antipathogen immune response can 
rapidly clear virus, it can also come at the cost of enhanced de-
struction of infected tissues. A previous study that tested treat-
ment of flu-infected mice with anti-ICOS antibody found that it 
reduced pulmonary T-cell inflammation [23], thus indicating a 
potential mechanism whereby reduced ICOS expression could 
benefit host survival after virus infection through reduction of 
tissue-specific inflammation.
Table 1. CC F1 Lines Grouped by Mortality Rates
Strain Flu SARS-CoV WNV
(CC003 × CC062)F1 0 0 0
(CC041 × CC016)F1 0 0 0
(CC029 × CC027)F1 0 0 0
(CC046 × CC068)F1 0 0 0
(CC012 × CC038)F1 0 0 0
(CC013 × CC041)F1 0 0 0
(CC030 × CC061)F1 0 0 0
(CC038 × CC013)F1 0 0 0
(CC001 × CC055)F1 8.7 8.0 50.0
(CC019 × CC027)F1 9.1 13.3 8.3
(CC040 × CC015)F1 58.3 3.8 33.3
(CC074 × CC062)F1 23.8 83.3 50.0
(CC074 × CC058)F1 16.7 54.5 33.3
(CC015 × CC059)F1 31.8 4.8 50.0
(CC075 × CC035)F1 8.7 11.5 41.7
(CC018 × CC065)F1 8.3 16.7 55.6
(CC035 × CC020)F1 7.7 5.6 66.7
(CC043 × CC033)F1 7.4 4.0 33.3
(CC052 × CC014)F1 8.3 10.0 33.3
Abbreviations: CC, Collaborative Cross; flu, H1N1 influenza; SARS-CoV, severe acute respi-
ratory syndrome-coronavirus; WNV, West Nile virus. 
Increased Frequencies of Regulatory T Cells at Steady-State Is Associated 
With Protection From Death After Infection
Based on our finding that distinct baseline T-cell activation 
states may play a role in protection from severe clinical outcomes 
such as mortality after viral infection (Figure 1), we next exam-
ined steady-state regulatory T-cell (Treg) frequency and pheno-
type in the spleen. A significantly higher baseline frequency of 
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Figure 1. A distinct baseline T-cell ratio and activation signature associates with protection from mortality after virus infections. Age-matched male or female CC-RIX were 
infected with H1N1 influenza, severe acute respiratory syndrome-coronavirus, or West Nile virus and monitored for survival. Based on these data, they were grouped into 
“No Mortality” or “Mortality in all 3” categories as shown in Table 1. A second cohort of 3–6 age-matched male mice of the same CC-RIX were euthanized, and splenic cells 
were analyzed by flow cytometry staining to determine the CD4:CD8 T-cell ratio, the frequency of CD3+ T-cells, the frequency of CD3+ T cells that were CD8+ or CD4+ (A), and 
the frequency of CD44+CD8 T cells (B), CD44+CD4 T cells (C), CXCR3+CD8 T cells (D), CD62L−CD4 T cells (E), Ki67+CD4 T cells (F), Tbet+CD8 T cells (G), Tbet+CD4 T cells (H), and 
inducible costimulator (ICOS)+ CD4 T cells (I). Statistical significance was determined by Mann-Whitney test.






































































































Figure 2. An increased frequency of regulatory T cells (Tregs) at steady-state predicts protection from death after subsequent virus infections. Age-matched male or female 
CC-RIX were infected with H1N1 influenza, severe acute respiratory syndrome-coronavirus, or West Nile virus and monitored for survival. Based on these data, they were
grouped into “No Mortality” or “Mortality in all 3” categories as shown in Table 1. A second cohort of 3–6 age-matched male mice of the same CC-RIX were euthanized, and 
splenic cells were analyzed by flow cytometry staining to determine the frequency of Foxp3+ Tregs (A), CD44+ Tregs (B), glucocorticoid-induced tumor necrosis factor receptor 
(GITR)+ Tregs (C), and CD25+ Tregs (D). Statistical significance was determined by Mann-Whitney test.
Tregs that express activation markers CD44 and glucocorticoid-
induced tumor necrosis factor (TNF) receptor (GITR) (Figure 
2B and C), is present in mice from lines that are protected from 
death after infection. This is consistent with the notion that a 
homeostatic state of immune quiescence mediated at least in 
part by Tregs could play a role in protection from severe clinical 
outcomes after virus infection. It is interesting to note that we 
found a decreased frequency of Tregs expressing CD25 in mice 
from lines with no mortality after virus infections (Figure 2D 
and Supplementary Figure S2). CD25 expression affords Tregs 
the ability to be competitive consumers of interleukin (IL)-2, 
thereby depriving conventional CD4 T cells of this essential cy-
tokine and thus restricting their expansion [24, 25]. Thus, it is 
possible that the reduced frequency of CD25+ Tregs indicates 
less and/or altered suppressive capacity by Tregs, which could 
be critical for maintaining a balance of robust immunity that 
can clear virus with limitation of immunopathology-driven dis-
ease, morbidity, and mortality.
Enhanced T-Cell Production of Proinflammatory Cytokines at Baseline Is 
Associated With Increased Risk of Death After Virus Infection
To further investigate our hypothesis of the need for a balanced 
state of appropriately tuned immune responses to survive viral 
infection, we examined T-cell capacity to produce cytokines at 
the steady state. There is no difference in CD8 T-cell or CD4 
T-cell production of IFNγ at baseline in mice from lines with or 
without mortality (Figure 3A and D). Although the frequency
of T cells producing IL-17 is very low at baseline, there is a sig-
nificant, more than 3-fold increase in the fraction of CD8 and
CD4 T cells producing IL-17 in mice from lines that were pro-
tected from death after viral challenge (Figure 3B and E and
Supplementary Table 2). Th17 cells are best known for their
roles in immunosurveillance of mucosal barrier surfaces and
in many autoimmune and inflammatory diseases. The role of
IL-17 during intracellular and viral infections remains unclear,
because there is evidence both for protective and pathological
roles [26, 27]. Finally, we observed that a reduced frequency
of CD8 and CD4 T cells producing TNFα at baseline is asso-
ciated with protection from mortality upon virus infections
(Figure 3C and F). We hypothesize that a propensity to produce 
this proinflammatory cytokine could play a detrimental role in
immune-mediated tissue damage upon infection, consistent
with previous findings with SARS-CoV [28], and perhaps this
could serve as a biomarker for individuals who may be at higher 
risk of severe clinical disease upon virus infections.
DISCUSSION
We used CC mice in combination with a large screen of 
postinfection mortality after infection with flu, SARS-CoV, and 
WNV to identify immune correlates of protection from severe 
clinical outcome, as indicated by death. Through this study, we 
have identified several baseline immunological features that may 
contribute to protection from severe disease and clinical out-
comes upon virus infections of many kinds. These include a lower 
CD4:CD8 T-cell ratio, thereby indicating that CD8 T cells may 
play a key role in mediating this balance between clearing path-
ogen while sparing collateral damage to host tissues. Moreover, 
an increased level of basal T-cell activation is associated with pro-
tection, and given that CD44+, a marker associated with T-cell 
memory, is one of the markers found in this signature (Figure 
1B and C), it is possible that rapid bystander activity may play a 
critical role in this protective response. These CD44+ T cells may 
represent true memory T cells that have resulted from previous 
microbial exposures, because these mice were housed in specific 
pathogen-free (SPF) but not germ-free conditions. Alternatively, 
these cells could also represent unconventional memory pheno-
type cells that acquired a memory phenotype without exposure 
to cognate antigen [29–33]. In either case, however, it is possible 
that these cells could participate in early viral control through 
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Figure 3. Enhanced T cell-mediated proinflammatory cytokine potential at 
baseline is associated with risk of death after virus infections. Age-matched 
male or female CC-RIX were infected with H1N1 influenza, severe acute res-
piratory syndrome-coronavirus, or West Nile virus and monitored for survival. 
Based on these data, they were grouped into “No Mortality” or “Mortality in all 
3” categories as shown in Table 1. A second cohort of 3–6 age-matched male 
mice of the same CC-RIX were euthanized, and splenic cells were treated with 
anti-CD3/CD28 for intracellular cytokine staining assessment of interferon (IFN)γ 
(A and D), interleukin (IL)-17 (B and E), and tumor necrosis factor (TNF)α (C and F) 
expression by CD8 (A–C) and CD4 (D–F) T cells. Statistical significance was de-
termined by Mann-Whitney test.
advantage to the host through rapid viral containment before the 
generation of a virus-specific T-cell response [34]. Indeed, this 
would be consistent with previous findings that unconventional 
memory T cells proliferate rapidly in response to antigen [35] 
and can participate in protective immunity against pathogens 
such as Listeria monocytogenes and influenza virus [36–38]. In 
addition, we found that an increased frequency of Tregs with a 
unique suppressive profile correlated with protection (Figure 2), 
which supports the notion that balance between active immu-
nity and suppression is likely critical to spare the host from severe 
disease after infection. We have previously found that Tregs can 
play a role in protection from human immunodeficiency virus 
infection through analysis of a case-control cohort [39], and, in 
addition, there is precedent for Tregs playing a role in protection 
from immunopathology after infection [40–42]. Furthermore, it 
has previously been shown that Treg activity is required during 
viral infections to allow for appropriate generation and migration 
of immune effector cells to the site of infection [43–45]. Thus, it 
is possible that this increased Treg abundance and expression of 
the suppressive marker GITR play a role in coordinating effec-
tive antiviral immunity. Alternatively, it is also possible that Tregs 
could assist in attenuating antiviral immunity upon viral clear-
ance, thereby sparing the host additional collateral damage that 
could be associated with a prolonged active immune response. 
The results, taken together, argue that an augmented but targeted 
T-cell response plays a role in resistance to viral-induced mor-
tality. Finally, a reduced steady-state T-cell capacity to produce
the proinflammatory cytokine TNFα is correlated with protec-
tion, which is consistent with less risk of collateral damage upon
T-cell receptor-mediated stimulation. We hypothesize that the
CD44+ memory-phenotype CD8 T cells, found in greater steady-
state abundance in CC-RIX that did not suffer from mortality
upon infection, do not confer protection via a canonical, antigen-
specific “true memory”-mediated mechanism such as cytokine
production. Instead, we speculate that these CD44+CD8+ T
cells become bystander-activated during inflammation asso-
ciated with infection, and thus they acquire cytotoxic function
that could be mediated by alternative pathways such as NKG2D-
mediated target cell killing [34]. Altogether, these observations
distinguish a T-cell profile associated with protection from viral-
induced mortality.
Due to the nature of this large, collaborative study that 
used thousands of mice over the course of several years, there 
are some limitations to discuss. All mice for the project were 
obtained from the Systems Genetics Core Facility located at 
UNC. These mice were used for flu and SARS-CoV experiments 
at UNC or for WNV experiments, including flow cytometry-
based immune phenotyping of naive and infected mice, at the 
UW. To reduce the amount of breeding as well as the produc-
tion and use of mice, we used female mice for flu and SARS-
CoV studies at UNC, and male mice were used for WNV 
studies at UW. Thus, although only males were used for baseline 
splenic immunophenotyping, and males (WNV) and females 
(influenza and SARS-CoV) were used for infection studies 
that yielded data on mortality, this ensured that any correlates 
of protection identified in this analysis were not sex-specific. 
Moreover, we examined immune cells from the spleen by flow 
cytometry, as a measure of preinfection immune phenotypes, 
but we did not examine blood or other viral target tissue such as 
the lung, using this same flow cytometry panel. Thus, we cannot 
speculate on preinfection lung immunophenotypes associated 
with viral infection outcomes. In addition, most human data 
comes from analysis of immune cells within the blood, and al-
though our analysis of immune cells within the spleen can be 
used to predict what might be protective in humans, it is not 
the most common tissue type analyzed, and thus a direct blood-
to-blood comparison is not possible from our study. In addi-
tion, the majority of immune phenotypes screened for represent 
T-cell phenotypes, and there are likely other innate and humoral 
immune states that could be associated with mortality, and this
warrants further study. Finally, although the results presented
herein demonstrate an association between a set of baseline
T-cell immunophenotypes and protection from mortality upon
infection with ribonucleic acid viruses, we have not tested these 
predictions through mechanistic study. However, we specu-
late that it is not 1 single immune phenotype that solely drives
protection from mortality, and so we predict that blocking or
augmenting a single immune phenotype alone would not sig-
nificantly alter the degree of mortality upon infection.
CONCLUSIONS
Overall, our results define distinct baseline T-cell correlates as-
sociated with survival after viral challenge. This study not only 
identifies specific basal immune characteristics that are associ-
ated with protection from mortality upon virus infections, but 
it also underscores the need for a protective immune response 
to be balanced to protect the host not only from uncontrolled 
virus replication but also from disease associated with robust 
immunity. Although validation studies in humans are required 
to confirm these correlates of protection from severe clinical 
disease after virus infection, it is possible that this knowledge 
can advance efforts to design vaccines and other infection 
prevention strategies. Likewise, the T-cell profile can inform 
methods by which to screen for individuals at increased risk of 
severe clinical disease upon virus infections. More important, 
the approach highlights the utility of exploring multiple infec-
tions in the context of a genetically diverse populations.
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Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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